In an interesting debate session at the European Atherosclerosis Society (EAS) 2022, Michal Vrablík, Czech Republic, and Ulrich Laufs, Germany, argued whether oral lipid-lowering therapies such as statins and ezetimibe are sufficient for cardiovascular disease (CVD) prevention or whether we need the support of injectables, i.e, proprotein convertase subtilisin/kexin type...
EAS 2022 — Do we really need injectable lipid-lowering therapies for CVD prevention?
Pavankumar Kamat | Conference Report | 27 May 2022
Register or log in to read more
Registration is free and easy, giving you complete access to all Univadis content.Create a Free Account I have an account